Lilly Asia Ventures
Hansen Xu, Ph.D., is an Investment Manager with Lilly Asia Ventures (LAV). Prior to joining LAV, Hansen was a Project Leader and a member of the healthcare practice at Boston Consulting Group (BCG) Shanghai office, helping MNC and local pharma/biotech clients on various projects such as long term strategy, portfolio strategy, product launch support, and organizational structure changes among others. Hansen holds a Ph.D. in biochemistry from Cornell University and a B.A. in Chemistry from Cornell University.
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.